Pfizer scrip is currently trading at Rs. 2583.10, up by 49.00 points or 1.93% from its previous closing of Rs. 2534.10 on the BSE.
The scrip opened at Rs. 2530.00 and has touched a high and low of Rs. 2597.05 and Rs. 2525.00 respectively. So far 359 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2670.00 on 20-Jun-2018 and a 52 week low of Rs. 1701.00 on 12-Oct-2017.
Last one week high and low of the scrip stood at Rs. 2,597.05 and Rs. 2505.00 respectively. The current market cap of the company is Rs. 11825.79 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 14.92% and 21.16% respectively.
Pfizer is reportedly planning to split its business into three units and one of them would include a new hospital business segment. The three new units of the company will be established medicines, consumer healthcare and innovative medicines. The innovative medicines business and consumer healthcare would together comprise about three-quarter of its revenue based on 2017 results.
The company’s new business structure represents a natural evolution, ongoing strength in-market products and late-stage pipeline and the expected significant reduction in the impact of patent protection losses post-2020.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1811.35 |
Dr. Reddys Lab | 1220.00 |
Cipla | 1499.60 |
Lupin | 2097.70 |
Zydus Lifesciences | 956.95 |
View more.. |